| Primary | Sum of Pain Intensity Differences (SPID) Over 48 Hours | Pain Intensity (PI) was assessed on an 11-point numerical rating scale from 0=no pain to 10=pain as bad as you can imagine. PID was the difference between baseline PI (prior to the first dose) and current PI at assessment. SPID was calculated as the time-weighted Sum of PID scores over 48 hours. Total score ranges from -480 (worst) to 480 (best) for SPID48. A higher value of SPID indicates greater pain relief. | Intent-to-treat (ITT) analysis set, which included all randomized participants with at least 1 dose of study medication. Last-observation-carried-forward imputation method used for missing values. | Posted | | Mean | Standard Deviation | Scores on a scale | | 48 hours | | | | ID | Title | Description |
|---|
| OG000 | Placebo | Each participant received matching placebo once every 4 to 6 hours for 3 days | | OG001 | Tapentadol IR 50 mg | Each participant received 50 mg of Tapentadol immediate release (IR) once every 4 to 6 hours for 3 days | | OG002 | Tapentadol IR 75 mg | Each participant received 75 mg of Tapentadol immediate release (IR) once every 4 to 6 hours for 3 days |
| | | Title | Denominators | Categories |
|---|
| | | Title | Measurements |
|---|
| - OG00065.3± 121.04
- OG001131.7± 107.19
- OG002154.5± 124.03
|
|
| | Group IDs | Group Description | Statistical Method | Statistical Comment | P-Value | P-Value Comment | Parameter Type | Parameter Value | Dispersion Type | Dispersion Value | Confidence Interval Sides | Confidence Interval % | CI Lower Limit | CI Upper Limit | CI Lower Limit Comment | CI Upper Limit Comment | Estimate Comment | Tested Non-Inferiority | Non-Inferiority Type | Non-Inferiority Comment | Other Analysis Description |
|---|
| | ANCOVA | ANCOVA model with treatment group and center as factors and baseline pain intensity as covariate. | <0.001 | P-value adjusted for multiple treatment group comparisons using the Hochberg method. | Mean Difference (Net) | 76.35 | | | 2-Sided | 95 | 51.0 | 101.7 | | | Difference is SPID48 in tapentadol IR group minus SPID48 in placebo group. | No | Superiority or Other | | | |
|
| Secondary | Time to First Rescue Medication Use | Rescue medication was defined as any analgesic medication used for participants discontinued due to lack of efficacy (including those started at time of discontinuation) or analgesic medication used during the double-blind period for completed participants. | Intent-to-treat (ITT) analysis set, which included all randomized participants with at least 1 dose of study medication. | Posted | | Median | Inter-Quartile Range | Hours | | Up to 48 hours | | | | ID | Title | Description |
|---|
| OG000 | Placebo | Each participant received matching placebo once every 4 to 6 hours for 3 days | | OG001 | Tapentadol IR 50 mg | Each participant received 50 mg of Tapentadol immediate release (IR) once every 4 to 6 hours for 3 days | | OG002 | Tapentadol IR 75 mg | Each participant received 75 mg of Tapentadol immediate release (IR) once every 4 to 6 hours for 3 days |
| |
| Secondary | Percent Reduction in Pain Intensity From Baseline at 12, 24, 48, and 72 Hours | Pain intensity was assessed on a 11-point numerical rating scale from 0=no pain to 10=pain as bad as you can imagine. Participants with no assessment at the given time point, who used an analgesic medication prior to the time point, or who had worse pain intensity at the time point compared to baseline were assigned a percent reduction of 0 percent. | Intent-to-treat (ITT) analysis set, which included all randomized participants with at least 1 dose of study medication. | Posted | | Median | Inter-Quartile Range | Percentage Reduction | | Baseline (Day 1) and 12, 24, 48, and 72 hours | | | | ID | Title | Description |
|---|
| OG000 | Placebo | Each participant received matching placebo once every 4 to 6 hours for 3 days | | OG001 | Tapentadol IR 50 mg | Each participant received 50 mg of Tapentadol immediate release (IR) once every 4 to 6 hours for 3 days | | OG002 | Tapentadol IR 75 mg | Each participant received 75 mg of Tapentadol immediate release (IR) once every 4 to 6 hours for 3 days |
| |
| Secondary | Response Rate for 30 Percent or Greater Reduction in Pain Intensity at 12, 24, 48, and 72 Hours | Response rate was defined as the percentage of participants with a 30 percent or greater reduction in pain intensity from baseline to 12, 24, 48, and 72 hours. Pain intensity was assessed on a 11-point numerical rating scale from 0=no pain to 10=pain as bad as you can imagine. Participants with no assessment at the given time point, who used an analgesic medication prior to the time point, or who had worse pain intensity at the time point compared to baseline were assigned a percent reduction of 0 percent. | Intent-to-treat (ITT) analysis set, which included all randomized participants with at least 1 dose of study medication. | Posted | | Number | | Percentage of participants | | 12, 24, 48, and 72 hours | | | | ID | Title | Description |
|---|
| OG000 | Placebo | Each participant received matching placebo once every 4 to 6 hours for 3 days | | OG001 | Tapentadol IR 50 mg | Each participant received 50 mg of Tapentadol immediate release (IR) once every 4 to 6 hours for 3 days | | OG002 | Tapentadol IR 75 mg | Each participant received 75 mg of Tapentadol immediate release (IR) once every 4 to 6 hours for 3 days |
|
| Secondary | Response Rate for 50 Percent or Greater Reduction in Pain Intensity at 12, 24, 48, and 72 Hours | Response rate was defined as the percentage of participants with a 50 percent or greater reduction in pain intensity from baseline to 12, 24, 48, and 72 hours. Pain intensity was assessed on a 11-point numerical rating scale from 0=no pain to 10=pain as bad as you can imagine. Participants with no assessment at the given time point, who used an analgesic medication prior to the time point, or who had worse pain intensity at the time point compared to baseline were assigned a percent reduction of 0 percent. | Intent-to-treat (ITT) analysis set, which included all randomized participants with at least 1 dose of study medication. | Posted | | Number | | Percentage of participants | | 12, 24, 48, and 72 hours | | | | ID | Title | Description |
|---|
| OG000 | Placebo | Each participant received matching placebo once every 4 to 6 hours for 3 days | | OG001 | Tapentadol IR 50 mg | Each participant received 50 mg of Tapentadol immediate release (IR) once every 4 to 6 hours for 3 days | | OG002 | Tapentadol IR 75 mg | Each participant received 75 mg of Tapentadol immediate release (IR) once every 4 to 6 hours for 3 days |
|
| Secondary | Sum of Pain Intensity Differences (SPID) Over 12, 24, and 72 Hours | Pain Intensity (PI) was assessed on an 11-point numerical rating scale from 0=no pain to 10=pain as bad as you can imagine. PID was the difference between baseline PI (prior to the first dose) and current PI at assessment. SPID was calculated as the time-weighted Sum of PID scores over 12, 24, and 72 hours. Total score ranges from -120 (worst) to 120 (best) for SPID12, -240 (worst) to 240 (best) for SPID24, -720 (worst) to 720 (best) for SPID72. A higher value of SPID indicates greater pain relief. | Intent-to-treat (ITT) analysis set, which included all randomized participants with at least 1 dose of study medication. Last-observation-carried-forward imputation method used for missing values. | Posted | | Mean | Standard Deviation | Scores on a scale | | 12, 24, and 72 hours | | | | ID | Title | Description |
|---|
| OG000 | Placebo | Each participant received matching placebo once every 4 to 6 hours for 3 days | | OG001 | Tapentadol IR 50 mg | Each participant received 50 mg of Tapentadol immediate release (IR) once every 4 to 6 hours for 3 days | | OG002 | Tapentadol IR 75 mg | Each participant received 75 mg of Tapentadol immediate release (IR) once every 4 to 6 hours for 3 days |
|
| Secondary | Total Pain Relief (TOTPAR) Over 12, 24, 48, and 72 Hours | Participants rated pain relief rated on 5-point categorical scale of 0-4 (0=none, 1=A little, 2=Some, 3=A lot, 4=Complete). Total Pain Relief (TOTPAR) was calculated as the time-weighted sum of pain relief scores up to Hour 12, 24, 48, and 72 hours. Total score ranges from 0 (worst) to 48 (best) for TOTPAR12, 0 (worst) to 96 (best) for TOTPAR24, 0 (worst) to 192 (best) for TOTPAR48, and 0 (worst) to 288 (best) for TOTPAR72. A higher value of TOTPAR indicated greater pain relief. | Intent-to-treat (ITT) analysis set, which included all randomized participants with at least 1 dose of study medication. Last-observation-carried-forward imputation method used for missing values | Posted | | Mean | Standard Deviation | Scores on a scale | | 12, 24, 48, and 72 hours | | | | ID | Title | Description |
|---|
| OG000 | Placebo | Each participant received matching placebo once every 4 to 6 hours for 3 days | | OG001 | Tapentadol IR 50 mg | Each participant received 50 mg of Tapentadol immediate release (IR) once every 4 to 6 hours for 3 days | | OG002 | Tapentadol IR 75 mg | Each participant received 75 mg of Tapentadol immediate release (IR) once every 4 to 6 hours for 3 days |
|
| Secondary | Sum of Pain Relief and Pain Intensity Differences (SPRID) Over 12, 24, 48, and 72 Hours | Participants rated pain relief rated on 5-point categorical scale of 0-4 (0=none, 1=A little, 2=Some, 3=A lot, 4=Complete). Pain Intensity (PI) was assessed on an 11-point numerical rating scale from 0=no pain to 10=pain as bad as you can imagine. PID was the difference between baseline PI (prior to the first dose) and current PI at assessment. PRID is the sum of pain relief and PID at the same assessment time. SPRID was calculated as the time-weighted Sum of PRID scores over 12, 24, 48, and 72 hours. Total score ranges from -120 (worst) to 168 (best) for SPRID12, -240 (worst) to 336 (best) for SPRID24, -480 (worst) to 672 (best) for SPRID48, and -720 (worst) to 1008 (best) for SPRID72. A higher value of SPRID indicates greater pain relief. | Intent-to-treat (ITT) analysis set, which included all randomized participants with at least 1 dose of study medication. Last-observation-carried-forward imputation method used for missing values. | Posted | | Mean | Standard Deviation | Scores on a scale | | 12, 24, 48, and 72 hours | | | | ID | Title | Description |
|---|
| OG000 | Placebo | Each participant received matching placebo once every 4 to 6 hours for 3 days | | OG001 | Tapentadol IR 50 mg | Each participant received 50 mg of Tapentadol immediate release (IR) once every 4 to 6 hours for 3 days | |
|
| Secondary | Patient Global Impression of Change (PGI-C) Score at 72 Hours | The PGI-C is a 7-point scale that requires the patients to assess how much their illness has improved or worsened relative to a baseline state at the beginning of the intervention. The response options are: 1=very much improved; 2=much improved; 3=minimally improved; 4=no change; 5=minimally worse; 6=much worse; and 7=very much worse. Higher scores indicate worsening. | Intent-to-treat (ITT) analysis set, which included all randomized participants with at least 1 dose of study medication. | Posted | | Number | | Percentage of participants | | Baseline (Day 1) and 72 hours | | | | ID | Title | Description |
|---|
| OG000 | Placebo | Each participant received matching placebo once every 4 to 6 hours for 3 days | | OG001 | Tapentadol IR 50 mg | Each participant received 50 mg of Tapentadol immediate release (IR) once every 4 to 6 hours for 3 days | | OG002 | Tapentadol IR 75 mg | Each participant received 75 mg of Tapentadol immediate release (IR) once every 4 to 6 hours for 3 days |
| |